Inflammatory Bowel Disease

Monogenic inflammatory bowel disease, while rare, has varied extra-intestinal comorbidities and limited treatments, according to a study published in Clinical Gastroenterology and Hepatology.

Lilly announced mirikizumab for treatment of ulcerative colitis met primary and secondary endpoints in the LUCENT-1 12-week, phase 3 induction study, according to a press release.

Regardless of prior tumor necrosis factor inhibitor failure status, Xeljanz was efficacious in patients with ulcerative colitis, according to a study published in Clinical Gastroenterology and Hepatology.

The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity profiles in patients with inflammatory bowel disease, according to study results.

Patients with ulcerative colitis treated with Entyvio had a lower risk for serious infections compared with those who received anti-TNF, according to study results.

Childhood exposure to residential greenspace was associated with a reduced risk for inflammatory bowel disease, according to data published in the American Journal of Gastroenterology.

These reports include new research on the impact of non-alcoholic fatty liver disease and diet, as well as news on the COVID-19 vaccine.

A recent study demonstrated an increased risk for organ failure and mortality among patients with acute pancreatitis and COVID-19. It was the top story in gastroenterology last week.

Gastroenterologists should feel comfortable educating patients that appropriate steps are being taken to ensure the COVID-19 vaccine is safe and effective, according to a report published in Clinical Gastroenterology and Hepatology.

In this exclusive video, Uma Mahadevan, MD, from the University of California, San Francisco, discusses the upcoming GUILD conference.